ArticleACR open rheumatology2023

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study.

Christopher T Ritchlin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.